BTIM Corp. reduced its position in Bristol-Myers Squibb Company (NYSE:BMY) by 1.3% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 19,490 shares of the biopharmaceutical company’s stock after selling 255 shares during the period. BTIM Corp.’s holdings in Bristol-Myers Squibb were worth $1,086,000 as of its most recent SEC filing.
Other hedge funds have also recently made changes to their positions in the company. American National Bank raised its position in shares of Bristol-Myers Squibb by 36.0% in the first quarter. American National Bank now owns 1,919 shares of the biopharmaceutical company’s stock worth $104,000 after buying an additional 508 shares in the last quarter. Welch Investments LLC raised its position in shares of Bristol-Myers Squibb by 3.9% in the first quarter. Welch Investments LLC now owns 2,109 shares of the biopharmaceutical company’s stock worth $115,000 after buying an additional 79 shares in the last quarter. Crestwood Advisors Group LLC bought a new position in shares of Bristol-Myers Squibb during the first quarter worth $116,000. Blue Chip Partners Inc. raised its position in shares of Bristol-Myers Squibb by 0.8% in the first quarter. Blue Chip Partners Inc. now owns 2,141 shares of the biopharmaceutical company’s stock worth $116,000 after buying an additional 17 shares in the last quarter. Finally, Proficio Capital Partners LLC raised its position in shares of Bristol-Myers Squibb by 29.6% in the first quarter. Proficio Capital Partners LLC now owns 2,204 shares of the biopharmaceutical company’s stock worth $119,000 after buying an additional 504 shares in the last quarter. 69.68% of the stock is owned by hedge funds and other institutional investors.
Bristol-Myers Squibb Company (BMY) traded down 0.0622% on Friday, reaching $56.7347. 1,848,546 shares of the company traded hands. The stock has a 50 day moving average of $55.93 and a 200-day moving average of $54.91. Bristol-Myers Squibb Company has a 1-year low of $46.01 and a 1-year high of $60.45. The stock has a market capitalization of $93.04 billion, a price-to-earnings ratio of 20.7212 and a beta of 1.17. Bristol-Myers Squibb also was the recipient of some unusual options trading activity on Thursday. Investors acquired 781 put options on the stock. This is an increase of approximately 117% compared to the typical daily volume of 360 put options.
Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported $0.74 earnings per share for the quarter, beating the consensus estimate of $0.73 by $0.01. Bristol-Myers Squibb had a net margin of 22.66% and a return on equity of 32.33%. The firm had revenue of $5.14 billion for the quarter, compared to analysts’ expectations of $5.09 billion. During the same quarter in the previous year, the company posted $0.69 EPS. The company’s revenue was up 5.6% compared to the same quarter last year. On average, equities analysts anticipate that Bristol-Myers Squibb Company will post $2.98 EPS for the current year.
The business also recently announced a quarterly dividend, which was paid on Tuesday, August 1st. Shareholders of record on Friday, July 7th were given a $0.39 dividend. The ex-dividend date of this dividend was Wednesday, July 5th. This represents a $1.56 dividend on an annualized basis and a yield of 2.75%. Bristol-Myers Squibb’s payout ratio is currently 56.73%.
A number of equities analysts recently weighed in on the stock. Credit Suisse Group set a $58.00 target price on shares of Bristol-Myers Squibb and gave the stock a “hold” rating in a research report on Wednesday. Vetr upgraded shares of Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating and set a $64.08 target price for the company in a research report on Thursday. BMO Capital Markets restated an “underperform” rating and set a $47.00 target price (down previously from $51.00) on shares of Bristol-Myers Squibb in a research report on Wednesday, July 26th. Leerink Swann dropped their target price on shares of Bristol-Myers Squibb from $66.00 to $61.00 and set an “outperform” rating for the company in a research report on Friday, July 28th. Finally, Goldman Sachs Group, Inc. (The) reiterated a “buy” rating and set a $63.00 price objective on shares of Bristol-Myers Squibb in a research report on Wednesday, August 9th. One equities research analyst has rated the stock with a sell rating, ten have issued a hold rating, eleven have given a buy rating and one has given a strong buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $62.12.
In related news, Director Theodore R. Samuels II bought 6,000 shares of the firm’s stock in a transaction on Wednesday, August 2nd. The shares were bought at an average price of $55.94 per share, with a total value of $335,640.00. Following the completion of the transaction, the director now directly owns 18,000 shares of the company’s stock, valued at approximately $1,006,920. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 0.23% of the company’s stock.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
What are top analysts saying about Bristol-Myers Squibb Company? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Bristol-Myers Squibb Company and related companies.